Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients

We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia. The proportions of patients achieving the optimal molecular responses at 3, 6, and 12  months, a major molecular response (MMR) rate and a complete cytogenetic response (CCyR) rate were 87.0, 87.0, 72.2, 45.8, and 72.7% for patients with dasatinib as second-line therapy, and 34.8, 34.8, 33.3, 20.8, and 46.2% as third-line therapy, respectively. A BCR-ABL1 transcript level on the Int ernational Scale (BCR-ABL1IS) of ≤10% at the initiation of ­dasatinib treatment was found to be associated with a higher probability of achieving MMR. Among patients with a ­BCR-ABL1IS higher than 10% at initiation of dasatinib treatment, dasatinib showed better performance as a second-line therapy than as a third-line therapy. The patients who achieved an optimal molecular response at 3 months had a superior cumulative incidence of MMR and CCyR compared with patients who failed to achieve such a response. Dasatinib induced considerable responses as a second-line treatment, especially in patients with a BCR-ABL1IS≤10% at initiation of treatment, whereas the efficacy was limited in patients receiving third-line therapy with a BCR-ABL1IS #x3e;10% at the initiation of treatment.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research

Related Links:

Tyrosine kinase inhibitors (TKIs) of aberrant tyrosine kinase (TK) activity have been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. An area of growing interest is the reported ability of TKIs to induce immunomodulatory effects with anti-tumor and anti-viral activity, which appears to be mediated by directly or indirectly acting on immune cells. In selected cases of patients with CML, TKI treatment may be interrupted and a non-drug remission may be observed. In these patients, an immune mechanism of increased anti-tumor cytotoxic activity induced by chronic administration of TKIs has been sugges...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.However, in most people with chronic myelogenous leukemia, cancerous stem cells remain in the body for years after their cancer has gone into remission. If treatment with imatinib or another similar medication is stopped — and in some cases, even while treatment continues — the leukemia stem cells can cause cancer to recur.Now, in experiments in mice as well as isolated human cancer ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Condition:   Chronic Myeloid Leukemia, Chronic Phase Interventions:   Drug: HQP1351;   Drug: Hydroxyurea or Interferon-based therapy;   Drug: Homoharringtonine;   Drug: Imatinib, Dasatinib or Nilotinib Sponsor:   Ascentage Pharma Group Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Thus, IFN-Ald40K with 12% residual activity and 62 hours of serum half-life proved to be a potent anticancerous and antiviral drug with enhanced serum retention time. PMID: 31612813 [PubMed - as supplied by publisher]
Source: Protein and Peptide Letters - Category: Biochemistry Authors: Tags: Protein Pept Lett Source Type: research
We present the case of a 68-year-old patient with a history of chronic myeloid leukemia, who presented with infectious polyarthritis, cervicalgia, torticollis and cervical impotence. Cervical radiography, CT, and MRI showed a C1-C2 subluxation adjacent to a pharyngeal abscess, so GS was diagnosed. After antibiotic therapy, the patient had to undergo surgery due to the failure of the closed reduction. Due to its low incidence, there are no clinical guidelines for the management of these patients; The interdisciplinary collaboration is fundamental to establish the opportune diagnosis that allows to establish the conservative...
Source: Neurocirugia - Category: Neurosurgery Authors: Tags: Neurocirugia (Astur) Source Type: research
In this study, we aimed to determine if simultaneous inhibition of BCR-ABL1 oncogenic tyrosine kinase and PAK1/2 serine/threonine kinase exert better anti-CML effect than that of individual treatments. PAK1 was inhibited by small-molecule inhibitor IPA-3 (p21-activated kinase inhibitor III), PAK2 was downregulated by specific short hairpin RNA (shRNA), and BCR-ABL1 tyrosine kinase was inhibited by imatinib (IM). The studies were conducted by using (i) primary CML-CP stem/early progenitor cells and normal hematopoietic counterparts isolated from the bone marrow of newly diagnosed patients with CML-CP and from healthy donors...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 5 October 2019Source: Sensors and Actuators B: ChemicalAuthor(s): Yang Li, Yanxin Chu, Yuanfang Li, Cheng Ma, Lingling LiAbstractThe detection of specific DNA sequences provides a powerful tool for early diagnosis and prevention of disease. Herein, an enzyme-free electrochemiluminescence (ECL) DNA biosensor was developed by coupling inorganic-organic nanocomposite as the luminophore and ZnCo2O4 as the efficient accelerator. ZnCo2O4 nanoparticles (ZCO NPs), derived from Co and Zn based bimetallic zeolite imidazole framework, was used as the ECL substrate due to their large surface area and...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
We report the case of a aCML patient successfully treated with AZA. A 66-year-old man with no remarkable medical history was admitted to our hospital because of leukocytosis. We diagnosed his disease as aCML and administered hydroxyurea (HU) and AZA. After four courses of AZA, his blood cell values improved, and he no longer needed transfusions and was able to stop HU. He continued receiving AZA without any severe complications. This is the first report that AZA is effective for the treatment of aCML.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Natural killer (NK) cells are large granular lymphocytes involved in our defense against certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti-tumor responses based on signals from activating and inhibitory cell surface receptors. They also lyse target cells via antibody-dependent cellular cytotoxicity, a critical mode of action of several therapeutic antibodies used to treat cancer. A body of evidence shows that NK cells can exhibit potent anti-tumor activity against chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). However, disease-...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 9 October 2019Source: The Journal of Molecular DiagnosticsAuthor(s): M. Isabel Prieto-Conde, Luis A. Corchete, María García-Álvarez, Cristina Jiménez, Alejandro Medina, Ana Balanzategui, Montserrat Hernández-Ruano, Rebeca Maldonado, M. Eugenia Sarasquete, Miguel Alcoceba, Noemí Puig, Verónica González-Calle, Ramón García-Sanz, Norma C. Gutiérrez, Marcos González-Díaz, María Carmen ChillónAbstractAcute myeloid leukemias (AMLs) are currently genomically characterized by karyotype, fluore...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
More News: China Health | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia